Table 1 Parameters of RA patients in three groups of remission, mild-to-moderate, and severe disease activity using ANOVA, chi-square, and Kruskal-Wallis test
Parameters | Remission (n = 111) mean ± SD or n (%) | Mild-to-moderate disease (n = 96) mean ± SD or n (%) | severe disease (n = 138) mean ± SD or n (%) | P-value |
|---|---|---|---|---|
Age (year) | 52.3 ± 11.5 | 51.1 ± 12.3 | 53.5 ± 12.9 | 0.345 |
Female | 83 (74.8%) | 74 (77.1%) | 114 (82.6%) | 0.300 |
Duration of RA disease (year) | 7.8 ± 8.3 | 8.8 ± 9.7 | 6.7 ± 6.6 | 0.155 |
Duration of thyroid disease (year) | 2.5 ± 7.1 | 1.4 ± 5.8 | 3.2 ± 7.0 | 0.117 |
Tender joint count | 0.1 ± 0.3 | 3.6 ± 2.7 | 14.1 ± 6.9 | < 0.001 |
Swollen joint count | 0.0 ± 0.2 | 3.4 ± 2.8 | 11.5 ± 6.4 | < 0.001 |
VAS | 4.7 ± 8.9 | 49.5 ± 31.7 | 90.6 ± 17.4 | < 0.001 |
DAS-28-ESR | 1.6 ± 0.5 | 4.1 ± 0.7 | 6.6 ± 0.9 | < 0.001 |
Laboratory findings | ||||
ESR (mm/h) | 10.9 ± 6.0 | 21.8 ± 15.6 | 40.9 ± 24.0 | < 0.001 |
CRP (mg/dl) | 3.2 ± 2.6 | 11.6 ± 12.8 | 24.5 ± 25.1 | < 0.001 |
TSH (mIU/L) | 2.3 ± 1.6 | 2.8 ± 2.2 | 3.4 ± 3.9 | 0.154 |
FT3 (pg/mL) | 3.0 ± 1.0 | 3.8 ± 1.7 | 4.7 ± 1.7 | < 0.001 |
FT4 (ng/dl) | 1.5 ± 1.0 | 1.9 ± 2.3 | 1.9 ± 2.7 | 0.219 |
Anti-TPO (IU/ml) | 64.1 ± 138.8 | 82.8 ± 154.9 | 146.7 ± 192.0 | < 0.001 |
Anti-CCP (U/ml) | 84.5 ± 129.7 | 87.0 ± 157.3 | 127.1 ± 147.4 | 0.019 |
Anti-MCV (U/ml) | 122.7 ± 266.0 | 232.3 ± 447.6 | 401.0 ± 421.9 | < 0.001 |
RF | 51 (45.9%) | 45 (47.9%) | 71 (52.2%) | 0.600 |
Medications | ||||
Prednisolone | 87 (78.4%) | 92 (95.8%) | 138 (100.0%) | < 0.001 |
Methotrexate | 88 (79.3%) | 82 (85.4%) | 131 (94.9%) | 0.001 |
Hydroxychloroquine | 45 (40.5%) | 58 (60.4%) | 104 (75.4%) | < 0.001 |
Leflunomide | 4 (3.6%) | 30 (31.3%) | 55 (39.9%) | < 0.001 |
Sulfasalazine | 16 (14.4%) | 21 (21.9%) | 52 (37.7%) | < 0.001 |
Etanercept | 2 (1.8%) | 1 (1.0%) | 3 (2.2%) | 0.807 |
Adalimumab | 0 (0.0%) | 4 (4.2%) | 6 (4.3%) | 0.087 |
Medication dosage | ||||
Prednisolone (mg/d) | 3.8 ± 2.9 | 7.5 ± 3.5 | 9.2 ± 2.9 | < 0.001 |
Methotrexate (mg/w) | 7.9 ± 5.8 | 11.8 ± 7.1 | 15.3 ± 6.4 | < 0.001 |
Hydroxychloroquine (mg/d) | 81.1 ± 101.4 | 135.5 ± 124.7 | 184.8 ± 129.5 | < 0.001 |
Leflunomide (mg/d) | 0.7 ± 3.7 | 6.2 ± 9.3 | 7.8 ± 9.8 | < 0.001 |
Sulfasalazine (g/d) | 0.2 ± 0.4 | 0.4 ± 0.8 | 0.7 ± 1.0 | < 0.001 |
Etanercept (mg/w) | 0.4 ± 3.3 | 0.3 ± 2.5 | 0.7 ± 5.2 | 0.805 |
Adalimumab (mg/2w) | 0.0 ± 0.0 | 1.5 ± 7.2 | 1.2 ± 5.8 | 0.087 |